Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,225 shares of the biopharmaceutical company's stock after selling 8,280 shares during the period. TD Private Client Wealth LLC's holdings in Gilead Sciences were worth $5,067,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the first quarter worth $25,000. Goodman Advisory Group LLC bought a new stake in Gilead Sciences in the first quarter worth $29,000. Annis Gardner Whiting Capital Advisors LLC raised its stake in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares in the last quarter. Core Alternative Capital lifted its position in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in Gilead Sciences during the fourth quarter valued at $41,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares of the company's stock, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock valued at $6,340,745 in the last 90 days. Company insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Trading Up 1.0%

Shares of NASDAQ:GILD traded up $1.08 during mid-day trading on Tuesday, reaching $112.86. 1,120,282 shares of the company were exchanged, compared to its average volume of 8,814,745. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a market cap of $140.39 billion, a price-to-earnings ratio of 23.76, a P/E/G ratio of 0.72 and a beta of 0.29. The firm's 50-day simple moving average is $107.12 and its 200 day simple moving average is $104.25. Gilead Sciences, Inc. has a 1 year low of $66.34 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same quarter last year, the company posted ($1.32) EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.80%. Gilead Sciences's dividend payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.